March 14th 2022
The associate professor from UC San Diego discussed the ongoing phase ½ trial of CTNS-RD
March 11th 2022
The director of research and development at AVROBIO discussed the molecular follow-up of cell therapies.
March 10th 2022
The senior vice president of clinical development at Passage Bio discussed biomarker activity seen in the IMAGINE-1 trial.
February 23rd 2022
The trial design was informed by both patient and physician perspectives.
February 15th 2022
Updated data were presented on LYS-SAF302 and LYS-GM101 at WORLDSymposium.
The director of research and development at AVROBIO discussed the analytical pipeline the company has developed for molecular follow-up of cell therapies.
February 14th 2022
The associate professor from UC San Diego discussed the curative potential of gene therapy in cystinosis.
Passage Bio presented data on both the Krabbe and GM1 gangliosidosis programs at WORLDSymposium.
February 13th 2022
Interim safety data from the FORTIS study were presented at WORLDSympsoium.
February 11th 2022
The senior vice president of clinical development at Passage Bio discussed new data from the IMAGINE-1 trial presented at WORLDSymposium.